ArticleInternational journal of clinical and experimental medicine2015
Identification of a novel molecular probe for recognition of human osteosarcoma cell using the cell-SELEX method.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Aptamers in Osteosarcoma: New Paths for Diagnosis and Treatment.Anti-cancer agents in medicinal chemistry · 2026Review
- Advances in Aptamer-Based Biosensors and Cell-Internalizing SELEX Technology for Diagnostic and Therapeutic Application.Biosensors · 2022Review
- In vitro selection of DNA aptamers against human osteosarcoma.Investigational new drugs · 2022Article
- Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease.Frontiers in pharmacology · 2022Review
- Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview.Journal of the Egyptian National Cancer Institute · 2021Review
- Aptamers: novelty tools for cancer biology.Oncotarget · 2018Review
- [Research advances in the role of aptamers in the diagnosis and targeted therapy of pediatric cancer].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Review
- Generating Cell Targeting Aptamers for Nanotheranostics Using Cell-SELEX.Theranostics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common primary malignant bone tumor in adolescents and young adults. The lack of specific probes for human osteosarcoma hinders the early diagnosis and treatment of metastatic disease. In the present study, we have designed a novel aptamer using the cell-based Systematic Evolution of Ligands Exponential Enrichment (cell-SELEX) technique that specifically recognizes the U-2 OS human osteosarcoma cell line. Candidate aptamer families were identified through nine rounds of selection followed by sequence analysis and fluorescent labeling in addition to specific binding to U-2 OS cells. We identified one aptamer that showed high affinity and specificity to target cells, but did not recognize non-osteosarcoma negative control tumor cell lines. Moreover, we show that the selected aptamer can effectively be used as a molecular probe for specific recognition of clinical osteosarcoma samples. The generation of aptamer libraries can be used not only for the specific diagnosis of osteosarcoma, but also to build a platform for developing probe-carrier-antitumor drugs complexes and targeted therapies for osteosarcoma.
Indexed as
Identifiers
26770413PMC4694313W2421834819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.